1. Home
  2. MNDO vs LEXX Comparison

MNDO vs LEXX Comparison

Compare MNDO & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MIND C.T.I. Ltd.

MNDO

MIND C.T.I. Ltd.

HOLD

Current Price

$1.23

Market Cap

24.4M

Sector

Technology

ML Signal

HOLD

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$1.06

Market Cap

22.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNDO
LEXX
Founded
1995
2004
Country
Israel
Canada
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.4M
22.7M
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
MNDO
LEXX
Price
$1.23
$1.06
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
52.3K
135.8K
Earning Date
11-12-2025
01-09-2026
Dividend Yield
17.89%
N/A
EPS Growth
N/A
N/A
EPS
0.14
N/A
Revenue
$19,770,000.00
$705,923.00
Revenue This Year
N/A
$13.35
Revenue Next Year
N/A
$78.83
P/E Ratio
$8.71
N/A
Revenue Growth
N/A
52.05
52 Week Low
$0.98
$0.77
52 Week High
$2.13
$2.85

Technical Indicators

Market Signals
Indicator
MNDO
LEXX
Relative Strength Index (RSI) 63.42 49.84
Support Level $1.18 $1.00
Resistance Level $1.22 $1.17
Average True Range (ATR) 0.03 0.08
MACD 0.00 -0.00
Stochastic Oscillator 90.00 41.49

Price Performance

Historical Comparison
MNDO
LEXX

About MNDO MIND C.T.I. Ltd.

MIND C.T.I. Ltd develops, manufactures, markets, and implements real-time and off-line convergent billing and customer care software solutions. It derives revenue from the sale of software products and services in two reportable segments, namely Billing and Related Services, which derives key revenue, and Messaging. The company has three product lines: Product Line A- billing and customer care solutions for service providers; Product Line B - call accounting and call management solutions for enterprises; and Product Line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in the Americas, Europe, Asia Pacific and Africa, and Israel. It earns maximum revenue from Europe.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

Share on Social Networks: